Depression 3D Printing for Blister Pack Tablet Formation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The existing methods for manufacturing pharmaceutical tablets, such as freeze-drying, face challenges including high energy and manpower costs, quality control issues, and unsuitability for certain drugs, while three-dimensional printing technologies waste significant amounts of unbound powder during the process.

Innovation Solution

The method of depression three-dimensional printing (3DP) forms bound-powder articles directly within packaging depressions, such as blister packs, by depositing powder and binding liquid in a pattern, reducing waste and improving efficiency, reproducibility, and product handling.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If freeze-drying method is used to manufacture tablets, then tablets can be formed in blister packs, but energy consumption increases and product activity is compromised

Engineering Contradiction:
Improvetablet formation in blister packVSAvoidenergy consumption
Core Design Contradiction:
Ease of manufactureVSUse of energy by moving object

Solution Approach 1:

The invention changes the fundamental parameters of the manufacturing process by replacing freeze-drying with a direct 3D printing method that deposits bound powder layers. This eliminates the need for freezing and sublimation steps, thereby reducing energy consumption while maintaining tablet formation capability in blister packs.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention substitutes the mechanical freeze-drying process with a controlled deposition process where binding liquid is applied to powder layers to form tablets directly. This replacement eliminates the complex thermal and phase-change mechanisms of freeze-drying, simplifying the manufacturing process and reducing energy requirements.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If three-dimensional printing is used to form dosage forms, then manufacturing efficiency improves, but unbound powder is wasted

Engineering Contradiction:
Improvemanufacturing efficiencyVSAvoidunbound powder waste
Core Design Contradiction:
ProductivityVSLoss of substance

Solution Approach 1:

The invention implements a powder recovery system that captures and reuses unbound powder after the binding liquid deposition process. The recovered powder is fed back into the 3D printing process, transforming what would be waste into a valuable resource and eliminating material loss while maintaining high manufacturing efficiency.

Inventive Principle:
Principle #34Discarding and recovering

Solution Approach 2:

The invention modifies the 3D printing process parameters by controlling the binding liquid deposition to achieve optimal binding efficiency. By adjusting parameters such as liquid flow rate, deposition speed, and powder layer thickness, the process maximizes the utilization of powder material, reducing unbound powder waste while maintaining productivity.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If freeze-drying method is used, then tablets can be produced, but quality control and regulatory requirements become more challenging

Engineering Contradiction:
Improveproduct quality consistencyVSAvoidquality control complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention replaces the complex freeze-drying process with a controlled 3D printing process where each layer of powder is precisely deposited and bound. This substitution simplifies quality control by eliminating the need to monitor complex thermal and phase-change parameters, while ensuring consistent product quality through programmable deposition control.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention incorporates feedback mechanisms in the 3D printing process to monitor and adjust deposition parameters in real-time. This feedback control ensures consistent tablet formation and facilitates easier quality control and regulatory compliance by providing traceable, controllable manufacturing parameters.

Inventive Principle:
Principle #23Feedback

4Ease of manufacture

If standard 3D printing process is used, then dosage forms can be formed, but unbound powder must be separated and recycled

Engineering Contradiction:
Improvedosage form formationVSAvoidtime for powder separation and recycling
Core Design Contradiction:
Ease of manufactureVSLoss of time

Solution Approach 1:

The invention implements an integrated powder recovery system that operates continuously during the 3D printing process. Unbound powder is captured and recovered immediately after each deposition cycle, eliminating the need for separate post-processing steps and reducing the time required for powder separation and recycling while maintaining ease of dosage form formation.

Inventive Principle:
Principle #34Discarding and recovering

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach minimizes waste, enhances product reproducibility, and allows for the formation of pharmaceutical tablets with improved handling and dispersion characteristics within their packaging, addressing the limitations of traditional methods.

Implementation Method 1

depositing a binding liquid in a pattern on the powder layer within the at least one depression, to bind at least a portion of the particles of the powder layer to form an incremental bound layer

Methodology Applied
Scientific EffectAdhesion: Adhesive

Data Source

PatentEP4140477A1Method and system for forming a dosage form within a packaging
Publication Date: 2023.03.01 APRECIA PHARMACEUTICALS LLC
  • EP4140477A1 patent drawingFigure 1~4
  • EP4140477A1 patent drawingFigure 5~10
  • EP4140477A1 patent drawingFigure 11~13

AI summary

A method and system of forming a pharmaceutical dosage form within a portion of a blister packaging. The method includes the steps of providing a blister packaging for the dosage form with depressions. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited into a substantially uniform powder layer within the depressions. A binding liquid is then deposited in a pattern on the powder layer within the depressions, to bind the particles of the powder layer and form an incremental wetted layer. Excess solvent in the binding material can be removed to form an incremental bound layer. These steps are repeated in sequence at least one or more times to form the pharmaceutical dosage form within the blister packaging.